|
Eine Ebene nach oben |
Gruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 19
2020
Michl, M.; Baumann, F. T.; Arends, J.; Erickson, N.; Würstlein, R. und Theurich, Sebastian
(17. November 2020):
Relevanz von Ernährungsstatus, Muskelmasse
und Stressstoffwechsel in der Tumortherapie.
In: Onkologie heute, Bd. 2020, Nr. 11: S. 44-50
Hack, C. C.; Haeberle, L.; Brucker, S. Y.; Janni, W.; Volz, B.; Loehberg, C. R.; Hartkopf, A. D.; Walter, C.-B.; Baake, G.; Fridman, A.; Malter, W.; Würstlein, R.; Harbeck, N.; Hoffmann, O.; Kuemmel, S.; Martin, B.; Thomssen, C.; Graf, H.; Wolf, C.; Lux, M. P.; Bayer, C. M.; Rauh, C.; Almstedt, K.; Gass, P.; Heindl, F.; Brodkorb, T.; Willer, L.; Lindner, C.; Kolberg, H-C; Krabisch, P.; Weigel, M.; Steinfeld-Birg, D.; Kohls, A.; Brucker, C.; Schulz, V.; Fischer, G.; Pelzer, V.; Rack, B.; Beckmann, M. W.; Fehm, T.; Rody, A.; Maass, N.; Hein, A.; Fasching, P. A. und Nabieva, N.
(2020):
Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients.
In: Breast, Bd. 50: S. 11-18
Montemurro, F.; Delaloge, S.; Barrios, C. H.; Würstlein, R.; Anton, A.; Brain, E.; Hatschek, T.; Kelly, C. M.; Pena-Murillo, C.; Yilmaz, M.; Donica, M. und Ellis, P.
(2020):
Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial.
In: Annals of Oncology, Bd. 31, Nr. 10: S. 1350-1358
2018
Nabieva, N.; Fehm, T.; Haeberle, L.; Waal, J. de; Rezai, M.; Baier, B.; Baake, G.; Kolberg, H. -C.; Guggenberger, M.; Warm, M.; Harbeck, N.; Würstlein, R.; Deuker, J. -U.; Dall, P.; Richter, B.; Wachsmann, G.; Brucker, C.; Siebers, J. W.; Popovic, M.; Kuhn, T.; Wolf, C.; Vollert, H. -W.; Breitbach, G. -P.; Janni, W.; Landthaler, R.; Kohls, A.; Rezek, D.; Noesselt, T.; Fischer, G.; Henschen, S.; Praetz, T.; Heyl, V.; Kuehn, T.; Krauss, T.; Thomssen, C.; Hohn, A.; Tesch, H.; Mundhenke, C.; Hein, A.; Hack, C. C.; Schmidt, K.; Belleville, E.; Brucker, S. Y.; Kuemmel, S.; Beckmann, M. W.; Wallwiener, D.; Hadji, P. und Fasching, P. A.
(2018):
Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study.
In: European Journal of Cancer, Bd. 96: S. 82-90
Witzel, I.; Laakmann, E.; Weide, R.; Neunhoeffer, T.; Park-Simon, T. -J.; Schmidt, M.; Fasching, P. A.; Hesse, T.; Polasik, A.; Mohrmann, S.; Wuerschmidt, F.; Schem, C.; Bechtner, C.; Würstlein, R.; Fehm, T.; Moebus, V.; Burchardi, N.; Loibl, S. und Müller, V.
(2018):
Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry.
In: European Journal of Cancer, Bd. 102: S. 1-9
Nabieva, N.; Kellner, S.; Fehm, T.; Häbrle, L.; Waal, J. de; Rezai, M.; Baier, B.; Baake, G.; Kolberg, H.-C.; Guggenberger, M.; Warm, M.; Harbeck, N.; Würstlein, R.; Deuker, J.-U.; Dall, P.; Richter, B.; Wachsmann, G.; Brucker, C.; Siebers, J. W.; Fersis, N.; Kuhn, T.; Wolf, C.; Vollert, H.-W.; Breitbach, G.-P.; Janni, W.; Landthaler, R.; Kohls, A.; Rezek, D.; Nösselt, T.; Fischer, G.; Henschen, S.; Prätz, T.; Heyl, V.; Kühn, T.; Krauss, T.; Thomssen, C.; Hohn, A.; esch, H.; Mundhenke, C.; Hein, A.; Rauh, C.; Bayer, C. M.; Jacob, A.; Schmidt, K.; Belleville, E.; Brucker, S. Y.; Kümmel, S.; Beckmann, M. W.; Wallwiener, D.; Hadji, P. und Fasching, P. A.
(2018):
Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients.
In: Annals of Oncology, Bd. 29, Nr. 1: S. 186-192
2017
Gluz, O.; Nitz, U.; Christgen, M.; Kates, R.; Clemens, M.; Nuding, B.; Shak, S.; Würstlein, R.; Kreipe, H. und Harbeck, N.
(2017):
Five-year results of the prospective Phase III WSG PlanB trial confirm prognostic impact of 21-Gene Recurrence Score in high-risk HR+/HER2-early breast cancer (EBC) patients with 1-3 involved lymph nodes.
In: Breast, Bd. 32:
S93-S93
Harbeck, N.; Nitz, U. A.; Matthias, C.; Kates, R.; Braun, M.; Kümmel, S.; Schumacher, C.; Potenberg, J.; Kraemer, S.; Kleine-Tebbe, A.; Augustin, D.; Aktas, B.; Forstbauer, H.; Tio, J.; Liedtke, C.; Grischke, E.-M.; Haas, S. L. de; Deurloo, R.; Schumacher, J.; Würstlein, R.; Kreipe, H. H. und Gluz, O.
(2017):
The role of immune and apoptosis markers for prediction of pCR in the WSG-ADAPT HER2+/HR+ phase II trial evaluating 12-weeks of neoadjuvant TDM1 +/- endocrine therapy (ET) versus T + ET in HER2-positive hormone-receptor-positive early breast cancer (EBC).
In: Cancer Research, Bd. 77
Brain, E.; Corradengo, D.; Oriana, N.; Piccardo, A.; Matteucci, F.; Cortes, J.; Harbeck, N.; Würstlein, R.; Piris, A.; Alberini, J.-L.; Merlo, D. F.; Degenhardt, T.; Turbiez, I.; Madar, O.; Monti, M.; Cesaro, A.; Rivitti, E.; Rollandi, G. A.; Iacozzi, M.; Campazzi, E.; Campora, S.; Camporese, D. und Gennari, A.
(2017):
Challenges faced across borders to open European academic multicentre projects: The ET-FES program part of the ERA-Net TRANSCAN JTC 2011.
In: Cancer Research, Bd. 77
Würstlein, R.; Grischke, E. M.; Gluz, O.; Kates, R.; Persoon, M.; Thill, M.; Hasmüller, S.; Knauer, M.; Pusch, R. und Harbeck, N.
(2017):
Impact of MammaPrint and BluePrint on early breast cancer treatment decisions: WSG PRIMe study results.
In: Breast, Bd. 32:
S107-S107
Corradini, S.; Schönecker, S.; Pazos, M.; Freislederer, P.; Reitz, D.; Ditsch, N.; Bodungen, V. von; Würstlein, R.; Harbeck, N. und Belka, C.
(2017):
DIBH radiotherapy in left-sided breast cancer patients using an optical surface scanning system.
In: Breast, Bd. 32:
S70-S71
Gluz, O.; Nitz, U.; Christgen, M.; Malter, W.; Clemens, M.; Reimer, T.; Nuding, B.; Aktas, B.; Stefek, A.; Ppllmanns, A.; Lorenz-Salehi, F.; Uleer, C.; Krabisch, P.; Kümmel, S.; Liedtke, C.; Shak, S.; Kates, R.; Würstlein, R.; Kreipe, H. H. und Harbeck, N.
(2017):
Prognostic impact of recurrence score (RS), grade/Ki67 central pathological review, and acycline (A)-free vs. A-containing chemotherapy (CT) on distant and locoregional disease-free survival (DDFS/LRFS) in high clinical risk HER2-early breast cancer (EBC): WSG PlanB trial results.
In: Annals of Oncology, Bd. 28
Nitz, U. A.; Gluz, O.; Christgen, M.; Grischke, E.-M.; Augustin, D.; Kümmel, S.; Braun, M.; Potenberg, J.; Kohls, A.; Krauss, K.; Stefek, A.; Schumacher, C.; Forstbauer, H.; Reimer, T.; Fischer, H.; Liedtke, C.; Würstlein, R.; Schumacher, J.; Kates, R.; Kreipe, H. und Harbeck, N.
(2017):
De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab +/- weekly paclitaxel.
In: Annals of Oncology, Bd. 28, Nr. 11: S. 2768-2772
Wonhöfer, M.; Schindler, F.; Welslau, M.; Würstlein, R.; Harbeck, N. und Schinköthe, T.
(2017):
Elderly patients do benefit from eHealth support.
In: Oncology Research and Treatment, Bd. 40: S. 264
Tiefenthaller, A.; Brix, N.; Escudero, Pazos M.; Kost, B.; Rack, B.; Bodungen, V. von; Weissenbacher, T.; Würstlein, R.; Rühle, P.; Gaipl, U.; Harbeck, N.; Belka, C.; Scheithauer, H. und Lauber, K.
(2017):
Immunologische Aspekte der intraoperativen Radiotherapie beim Mammakarzinom nach brusterhaltender Operation.
In: Strahlentherapie und Onkologie, Bd. 193:
S72-S72
Würstlein, R.; Gluz, O.; Kates, R.; Persoon, M.; Wasmayr, M.; Knauer, M.; Koplmüller, R.; Grischke, E.-M.; Schem, C.; Thill, M.; Hasmüller, S.; Griesinger, F.; Köhler, A.; Otremba, B.; Schindlbeck, C.; Reimer, T.; Krauter, J.; Tome, O.; Otto, F.; Friedrichs, K.; Albert, U.-S.; Gebauer, G.; Nitz, U. und Harbeck, N.
(2017):
Results of multigene assay (MammaPrint (R)) and molecular subtyping (BluePrint (R)) substantially impact treatment decision making in early breast cancer: Final analysis of the WSG PRIME decision impact study.
In: Cancer Research, Bd. 77
Montemurro, F.; Ellis, P.; Delaloge, S.; Würstlein, R.; Anton, A.; Button, P.; Lindegger, N. und Barrios, C.
(2017):
Safety and efficacy of trastuzumab emtansine (T-DM1) in 399 patients with central nervous system metastases: Exploratory subgroup analysis from the KAMILLA study.
In: Cancer Research, Bd. 77
2016
Schinköthe, T.; Harbeck, N.; Overkamp, F.; Weislau, M.; Würstlein, R. und Gieseler, F.
(2016):
CANKADO: First open eHealth platform for Oncology.
In: Oncology Research and Treatment, Bd. 39: S. 23
Liedtke, C.; Gluz, O.; Nitz, U.; Christgen, M.; Sotlar, K.; Grischke, E.-M.; Forstbauer, H.; Braun, M.; Warm, M.; Hackmann, J.; Uleer, C.; Aktas, B.; Schumacher, C.; Bangemann, N.; Linder, C.; Kümmel, S.; Clemens, M.; Potenberg, J.; Peter, S.; Kohls, A.; Pelz, E.; Kates, R. E.; Würstlein, R.; Kreipe, H. und Harbeck, N.
(2016):
Comparison of 12 weeks neoadjuvant Nab-Paclitaxel combined with Carboplatinum vs. Gemcitabine in triple negative breast cancer: WSG-ADAPT TN randomized phase II trial.
In: Oncology Research and Treatment, Bd. 39: S. 53